Last reviewed · How we verify

NCT04153812

Clinical Study on the Safety and Effectiveness of Vagus Nerve Stimulation in the Treatment of Refractory Depression

Status unknown Phase 1, PHASE2 Last updated 6 November 2019
What this trial tests

Phase 1, PHASE2 trial testing vagus nerve stimulation in Refractory Depression in 10 participants. Status unknown.

Timeline
1 November 2019
Primary endpoint
1 October 2021
30 May 2022

Quick facts

Lead sponsorXijing Hospital
PhasePhase 1, PHASE2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date1 November 2019
Primary completion1 October 2021
Estimated completion30 May 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xijing Hospital

Who can join

Adults 18 to 65, any sex, with Refractory Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Based on the mechanism hypothesis and clinical efficacy of VNS in treating refractory depression, this study will evaluate the safety and efficacy of VNS in treating refractory depression through a small sample of clinical trials

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Treatment resistance in psychiatry: state of the art and new directions.
    Howes OD, Thase ME, Pillinger T. · · 2022 · cited 250× · PMID 34257409 · DOI 10.1038/s41380-021-01200-3

Verify or expand the search:

Other trials of vagus nerve stimulation

Trials testing the same drug.

Other Xijing Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04153812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing